Company Filing History:
Years Active: 2010
Title: Tulu Buber: Innovator in TRPA1 Activation Inhibition
Introduction
Tulu Buber is an accomplished inventor based in Newtown, PA (US). He has made significant contributions to the field of pharmacology, particularly in the development of assays for screening compounds that modulate the activation of TRPA1, a transient receptor potential ion channel.
Latest Patents
Tulu Buber holds a patent for a "Screening assay for inhibitors of TRPA1 activation by a lower alkyl phenol." This invention relates to an assay that is useful for screening and identifying compounds as modulators of lower alkyl phenol activation of TRPA1. The patent addresses the challenges posed by thymol, a lower alkyl phenol that is commonly used as an anti-infective agent in products like mouthwashes. Thymol is known for its stringent properties and objectionable burning taste sensation, which can limit its acceptance in medical applications. The assay developed by Buber enables the measurement of TRPA1 activation and facilitates the screening of compounds that inhibit the activation caused by lower alkyl phenols, including thymol.
Career Highlights
Tulu Buber is currently associated with Redpoint Bio Corporation, where he continues to innovate in the field of drug development. His work focuses on enhancing the efficacy and acceptance of therapeutic agents by addressing taste-related issues.
Collaborations
Tulu collaborates with notable colleagues, including Seunghun Paul Lee and Qifeng Yang, who contribute to the research and development efforts at Redpoint Bio Corporation.
Conclusion
Tulu Buber's innovative work in developing assays for TRPA1 activation inhibition represents a significant advancement in pharmacology. His contributions are poised to improve the acceptance of important therapeutic agents in medical applications.